{"id":1843,"date":"2020-10-28T12:17:00","date_gmt":"2020-10-28T19:17:00","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=1843"},"modified":"2020-10-29T12:18:44","modified_gmt":"2020-10-29T19:18:44","slug":"declining-prevalence-of-antibody-positivity-to-sars-cov-2-a-community-study-of-365000-adults","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/10\/28\/declining-prevalence-of-antibody-positivity-to-sars-cov-2-a-community-study-of-365000-adults\/","title":{"rendered":"Declining Prevalence of Antibody Positivity to SARS-CoV-2 a Community Study of 365000 Adults"},"content":{"rendered":"<p><i>[Pre-print, not peer reviewed]<\/i> Results from 3 non-overlapping cohorts in the UK demonstrated that the overall prevalence of detectable IgG antibodies against SARS-CoV-2 declined by 27% (from 6.0% to 4.4%) between late June and September 2020. Greater levels of decline were seen among older people aged 75+ years (-39%) compared to those 18-24 years old (-15%) and people who did not report a history of COVID-19 symptoms (-64%) compared to those with SARS-CoV-2 infection confirmed on PCR (-22%).<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p><i>Ward et al. (Oct 27, 2020). Declining Prevalence of Antibody Positivity to SARS-CoV-2 a Community Study of 365000 Adults. Pre-print downloaded Oct 28 from <\/i><a href=\"https:\/\/doi.org\/10.1101\/2020.10.26.20219725\">https:\/\/doi.org\/10.1101\/2020.10.26.20219725<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer reviewed] Results from 3 non-overlapping cohorts in the UK demonstrated that the overall prevalence of detectable IgG antibodies against SARS-CoV-2 declined by 27% (from 6.0% to 4.4%) between late June and September 2020. Greater levels of decline were seen among older people aged 75+ years (-39%) compared to those 18-24 years old&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/10\/28\/declining-prevalence-of-antibody-positivity-to-sars-cov-2-a-community-study-of-365000-adults\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[67],"topic":[19],"class_list":["post-1843","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-antibodies","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/1843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=1843"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/1843\/revisions"}],"predecessor-version":[{"id":1844,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/1843\/revisions\/1844"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=1843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=1843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=1843"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=1843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}